Valeant wraps up its $11B Salix buyout; Bayer touts Eylea data from China;

@FiercePharma: Teva used kickbacks to boost Copaxone, Azilect scripts, feds say. FiercePharmaMarketing article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharma: Genentech expansion adds to Roche biologics buildout. It promises 100 jobs, $125M outlay. Story | Follow @EricPFierce

@CarlyHFierce: Final Four time: Four names, one crown: Trulicity, Vimizim star in the #FierceMadness Final Four push. Vote! | Follow @CarlyHFierce

> Valeant Pharmaceuticals ($VRX) wrapped up its $11 million buyout of the specialty drugmaker Salix Pharmaceuticals, grabbing that company's gastrointestinal drug portfolio in the process. Report

> Bayer said new study results from China show that Eylea works to improve vision in patients with wet age-related macular degeneration; the German drugmaker has asked regulators there to approve the med for that use. Report

> AstraZeneca ($AZN) started razing 450,000 square feet of former laboratory space at its North American headquarters in Delaware. Report

> A federal judge denied attempts by Millennium, Merck ($MRK) and Merck's Schering-Plough unit to nix kickback allegations in a whistleblower lawsuit over the drug Integrilin. Report

> Sanofi ($SNY) persuaded a U.S. judge to drop part of a whistleblower complaint against the company, but will have to face the rest of the off-label marketing suit. Report

Medical Device News

@FierceMedDev: Hansen eyes expansion for robotic surgery system with Chinese distribution deal. Story | Follow @FierceMedDev

@StacyALawrence: ICYMI: Philips brings in former Hologic CEO to head imaging biz in ongoing HealthTech revamp. Article | Follow @StacyALawrence

@VarunSaxena2: Japanese researchers study carbon nanotubes with drug delivery applications. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Get this week's ed. of FierceDiagnostics, feat. 23andMe's first foray into retail, $DGX and $Q's JV, and more. Issue | Follow @EmilyWFierce

> Sony sells off half its Olympus stake amid duodenoscope pushback. Report

> World's largest orthopedics contract manufacturer closing two plants. Story

> Orthofix restates earnings, gains option to buy migraine device startup eNeura for $65M. More

> Boston Scientific recalls its Expel biliary catheters after complaints of fragmentation. Article

Biotech News

@FierceBiotech: Prepping for a Duchenne study, Catabasis banks $12.4M in new fundraising. News | Follow @FierceBiotech

@JohnCFierce: Yale team says failed AstraZeneca drug shows promise in Alzheimer's. FierceBiotechResearch story | Follow @JohnCFierce

@DamianFierce: Serious question: Is the $SRPT hold muzak an instrumental of "I'm all out of love / I'm so lost without you?" | Follow @DamianFierce

> Roche CEO Schwan flags more biopharma partnering ahead. More

> Calico sheds light on its R&D mission with UCSF partnership. Report

> VC heavyweights back a $150M NYC biotech fund with Lilly and Celgene in tow. Article

Biotech Research News

> IL-17 may guard against skin infections in alcoholics. More

> Google-backed Calico in-licenses UCSF scientist's work on cognition. Report

> Professional societies flag key areas for COPD research. Item

> Yale team says failed AstraZeneca drug shows promise in Alzheimer's. Story

> Michigan investigators improve on a new approach to acute leukemia. Article

Diagnostics News

> Quest and Quintiles team up for JV aimed at clinical research, diagnostics. News

> White House calls for advancing rapid diagnostics to combat drug-resistant bacteria. More

> Bayer signs cardiovascular genomics alliance with Harvard, MIT. Report

> 23andMe dives into retail with U.K. deal for personal genome service. Story

> Cancer Dx startup Helomics joins U.K. genomics initiative alongside big biopharmas. Article

Pharma Marketing News

> Teva used kickbacks to boost Copaxone, Azilect scripts, feds say. News

> Celltrion eyes biosim Remicade launch in the U.S. this year. Item

> Vivus to slash obesity salesforce by one-third, turn to digital instead. Report

> Tiny Egalet scouting for 60 reps to hawk its new pain meds. Article

> Forget fighting over Flonase ads. GSK and J&J settle on fight for market share. Story

And Finally... How Sun Pharma CEO Dilip Shangvi became the richest Indian. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.